Tumor-to-Liver Ratio of Ga-68-DOTATOC PET/CT as a Prognostic Parameter in Metastatic, Well-Differentiated Gastroenteropancreatic-Neuroendocrine Tumor Patients Who Received Lanreotide Therapy Abstract #2777

Introduction: Lanreotide is a long-acting somatostatin analogue with proven antitumor effect against metastatic, well-differentiated gastroenteropancreatic-neuroendocrine tumors (GEP-NETs). Ga-68-DOTATOC PET/CT is a sensitive imaging technique for NETs by targeting somatostatin receptors.
Aim(s): We investigated the prognostic value of Ga-68-DOTATOC PET/CT in patients with metastatic, well-differentiated GEP-NETs treated by lanreotide.
Materials and methods: Thirty-one patients with metastatic, well-differentiated GEP-NETs were retrospectively enrolled (mean age; 55.1 ± 15.5 yr, M:F = 12:19). As clinicopathologic parameters, ECOG performance status, primary tumor site, WHO grade, presence of carcinoid symptom, prior surgery, prior chemotherapy, and hepatic tumor volume assessed by CT/MRI were identified. As Ga-68-DOTATOC PET/CT parameters, Krenning score, tumor-to-liver ratio (TLR), maximum standardized uptake value (SUVmax), whole tumor volume (WTV) and total receptor expression (WTV multiplied by SUVmean) were assessed. The primary endpoint was progression-free survival (PFS).
Conference: 17th Annual ENETS Conference 2020 (2020)
Category: Nuclear Medicine - Imaging and Therapy (PRRT)
Presenting Author: Yong-Il Kim

To read results and conclusion, please login ...

Further abstracts you may be interested in

#143 Association of somatostatin receptor 2 immunohistochemical expression with [111In]-DTPA octreotide scintigraphy and [68Ga]-DOTATOC PET/CT in neuroendocrine tumors
Introduction: In the absence of preoperative somatostatin receptor (sst) scans, knowledge of immunohistochemical sst2 tumor expression may help in predicting the success of somatostatin analogue-based follow-up studies and treatment of neuroendocrine tumors (NETs).
Conference: 7th Annual ENETS Conference (2010)
Category: Clinical
Presenting Author: Dr. Karsten Müssig
#365 FDOPA PET/CT has a Significant Clinical Impact on the Management of Patients with Neuroendocrine Tumors
Introduction: Studies suggest that positron emission tomography (PET) using the dopamine-synthesis tracer [18F]fluoro-dihydroxyphenylalanine (FDOPA) may improve the clinical management of patients with NET.
Conference:
Category: Basic
Presenting Author: Dr. Michael Sørensen
#484 Diagnostic Accuracy of Gallium-68 Somatostatin Receptor Positron Emission Tomography in Patients with Thoracic and Gastroenteropancreatic Neuroendocrine Tumors: A Meta-Analysis
Introduction: Gallium-68 somatostatin receptor (SMSR) positron emission tomography (PET) is a valuable diagnostic tool for patients with neuroendocrine tumors (NET). To date, a meta-analysis about the diagnostic accuracy of this functional imaging method is lacking.
Conference: 9th Annual ENETS Conference (2012)
Category: Clinical
Presenting Author: Dr. Giorgio Treglia
#1283 Heterotopic Pancreas Mimicking a Gastrointestinal Neuroendocrine Tumor: A Case Report
Introduction: Heterotopic pancreas, defined as an atypical presence of pancreatic tissue with no anatomic or vascular continuity with the pancreas, is relatively rare. In most cases it is diagnosed during autopsy or incidentally, since it becomes symptomatic only in few cases, causing bleeding, pain or obstruction.
Conference: 13th Annual ENETS conference 2016 (2016)
Category: Clinical cases/reports
Presenting Author: dr Sara Massironi
#1469 Theragnostic Approach of Gastroenteropancreatic Neuroendocrine Tumors (GEP-NET) – The Role of Nuclear Medicine (NM) in a Multidisciplinary Team
Introduction: NET pts are a clinical challenge requiring intervention of multiple medical specialties
Conference: 13th Annual ENETS conference 2016 (2016)
Category: PRRT-Ablative therapies-Endoscopic treatment
Presenting Author: Dr Teresa Lucio
Authors: Lucio T, Gaspar C, Cunha C, Roque R, ...
Keywords: PRRT, GEP-NET